Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A
Miho Nozaki, … , Balamurali K. Ambati, Jayakrishna Ambati
Miho Nozaki, … , Balamurali K. Ambati, Jayakrishna Ambati
Published February 1, 2006
Citation Information: J Clin Invest. 2006;116(2):422-429. https://doi.org/10.1172/JCI26316.
View: Text | PDF
Research Article Ophthalmology

Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A

  • Text
  • PDF
Abstract

VEGF-A promotes angiogenesis in many tissues. Here we report that choroidal neovascularization (CNV) incited by injury was increased by excess VEGF-A before injury but was suppressed by VEGF-A after injury. This unorthodox antiangiogenic effect was mediated via VEGFR-1 activation and VEGFR-2 deactivation, the latter via Src homology domain 2–containing (SH2-containing) tyrosine phosphatase-1 (SHP-1). The VEGFR-1–specific ligand placental growth factor-1 (PlGF-1), but not VEGF-E, which selectively binds VEGFR-2, mimicked these responses. Excess VEGF-A increased CNV before injury because VEGFR-1 activation was silenced by secreted protein, acidic and rich in cysteine (SPARC). The transient decline of SPARC after injury revealed a temporal window in which VEGF-A signaling was routed principally through VEGFR-1. These observations indicate that therapeutic design of VEGF-A inhibition should include consideration of the level and activity of SPARC.

Authors

Miho Nozaki, Eiji Sakurai, Brian J. Raisler, Judit Z. Baffi, Jassir Witta, Yuichiro Ogura, Rolf A. Brekken, E. Helene Sage, Balamurali K. Ambati, Jayakrishna Ambati

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Preexisting CNV inhibited subsequent CNV via VEGF-A. (A and B) Represent...
Preexisting CNV inhibited subsequent CNV via VEGF-A. (A and B) Representative choroidal flat mounts show that CNV lesions (insets show magnified images) were smaller in eyes (A) where preexisting laser injury (area denoted by arrow) was performed 2 days earlier compared with those in eyes (B) without prior injury. Arrowheads denote optic nerve. Scale bars: 200 μm. (C) Preexisting laser injury created 2 days before subsequent injury markedly decreased CNV in the subsequent laser spots near (∼0.75 mm) the preexisting injury and slightly decreased CNV in spots far (∼1.25 mm) from it. Preexisting laser injury created 14 days before subsequent injury in wild-type mice did not affect CNV of subsequent laser spots either near or far from preexisting injury. *P < 0.01 compared with eyes without preexisting injury; #P < 0.05 compared with far lesions in the day 2 group. n = 12 per data point. (D) Neutralizing anti–VEGF-A antibody reversed this inhibition in a dose-dependent manner. #P < 0.05 compared with no injection. n = 12 per data point. (C and D).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts